Search Results - "Watkins, Marcus P."

FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma by Russler-Germain, David A., Calhoun, Brendan R., Wu, Ningying, Watkins, Marcus P., Siegel, Barry A., Bartlett, Nancy L., Mhlanga, Joyce C.

Get full text

Molecular Mechanisms of Osteoblast/Osteocyte Regulation by Connexin43 by Stains, Joseph P., Watkins, Marcus P., Grimston, Susan K., Hebert, Carla, Civitelli, Roberto

“…Osteoblasts, osteocytes, and osteoprogenitor cells are interconnected into a functional network by gap junctions formed primarily by connexin43 (Cx43). Over…”
Get full text

Enhanced periosteal and endocortical responses to axial tibial compression loading in conditional connexin43 deficient mice by Grimston, Susan K, Watkins, Marcus P, Brodt, Michael D, Silva, Matthew J, Civitelli, Roberto

“…The gap junction protein, connexin43 (Cx43) is involved in mechanotransduction in bone. Recent studies using in vivo models of conditional Cx43 gene (Gja1)…”
Get full text

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma by Fehniger, Todd A, Watkins, Marcus P, Ezenwajiaku, Nkiruka, Wan, Fei, Hurd, David D, Cashen, Amanda F, Blum, Kristie A, Goy, Andre, Fenske, Timothy S, Wagner-Johnston, Nina D, Carson, Kenneth, Siegel, Marilyn J, Russler-Germain, David, Schneider, Stephanie E, Mehta-Shah, Neha, Kahl, Brad, Bartlett, Nancy L

Get full text

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas by Watkins, Marcus P, Bartlett, Nancy L

“…Ubiquitous expression of CD19 on B cell non-Hodgkin lymphoma identified it as a potential target for immune-based therapies. This article reviews the current…”
Get more information

Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma by Malecek, Mary-Kate, Watkins, Marcus P, Bartlett, Nancy L

“…Polatuzumab vedotin is an antibody-drug conjugate comprised of an anti-CD79b monoclonal antibody conjugated to monomethyl auristatin (MMAE), a…”
Get more information

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma by Ward, Jeffrey P., Berrien-Elliott, Melissa M., Gomez, Felicia, Luo, Jingqin, Becker-Hapak, Michelle, Cashen, Amanda F., Wagner-Johnston, Nina D., Maddocks, Kami, Mosior, Matthew, Foster, Mark, Krysiak, Kilannin, Schmidt, Alina, Skidmore, Zachary L., Desai, Sweta, Watkins, Marcus P., Fischer, Anne, Griffith, Malachi, Griffith, Obi L., Fehniger, Todd A., Bartlett, Nancy L.

“…New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for…”
Get full text

FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV max as a predictive biomarker in frontline treatment of mantle cell lymphoma by Russler-Germain, David A, Calhoun, Brendan R, Wu, Ningying, Watkins, Marcus P, Siegel, Barry A, Bartlett, Nancy L, Mhlanga, Joyce C

Get full text

A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma by Russler-Germain, David A., Watkins, Marcus P., Bartlett, Nancy L.

Get full text

COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience by Mehta-Shah, Neha, Bartlett, Nancy L., Kahl, Brad, Watkins, Marcus P., Dubois, Amalia, Schmelzle, Gabby, Waqar, Saiama, Ballman, Claire, Wan, Fei, Farnsworth, Christopher W.

Get full text

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma by Cortese, Matthew J., Wei, Wei, Cerdeña, Sebastian, Watkins, Marcus P., Olson, Marissa, Jodon, Gray, Kaiser, Jeff, Haverkos, Bradley, Hughes, Mitchell E., Namoglu, Esin, Grover, Natalie S., Snow, Anson, Orellana-Noia, Victor, Rainey, Magdalena, Sohail, Mohammad, Rudoni, Joslyn, Portell, Craig, Voorhees, Timothy, Landsburg, Daniel J., Kamdar, Manali, Kahl, Brad S., Hill, Brian T.

“…Patients with double- and triple-hit lymphomas (DHL/THL) have inferior outcomes with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone…”
Get full text

Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound‐Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine‐Needle Aspiration of Peripheral Lymph Nodes by Drylewicz, Monica R., Watkins, Marcus P., Shetty, Anup S., Lin, Michael F., Salter, Amber, Bartlett, Nancy L., Middleton, William D., Yano, Motoyo

“…Objectives Image‐guided tissue sampling in the workup of suspected lymphoma can be performed by core needle biopsy (CNB) or CNB with fine‐needle aspiration…”
Get full text

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience by Hamid, Muhammad Saad, Rutherford, Sarah C., Jang, Hyejeong, Kim, Seongho, Patel, Krish, Bartlett, Nancy L., Malecek, Mary-Kate, Watkins, Marcus P., Maddocks, Kami J., Bond, David A., Feldman, Tatyana A., Magarelli, Gabriela, Advani, Ranjana H, Spinner, Michael A, Evens, Andrew M., Shah, Mansi, Ahmed, Sairah, Stephens, Deborah M., Allen, Pamela, Tees, Michael T., Karmali, Reem, Cheson, Bruce D., Yazdy, Maryam Sarraf, Strouse, Christopher, Bailey, Neil A., Pagel, John M., Ramchandren, Radhakrishnan

“…The utility of dose escalation after positive positron emission tomography following 2 cycles of ABVD (PET2) for Hodgkin Lymphoma (HL) remains controversial…”
Get full text

Donor-Derived Follicular Lymphoma After Kidney Transplantation: A Case Report by Singhal, Kartik, Watkins, Marcus P, Fehniger, Todd A, Griffith, Malachi, Griffith, Obi L, Kahl, Brad S, Russler-Germain, David A

Get more information

Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice by Watkins, Marcus P, Norris, Jin Yi, Grimston, Susan K, Zhang, Xiaowen, Phipps, Roger J, Ebetino, Frank H, Civitelli, Roberto

“…Abstract The gap junction protein, connexin43 (Cx43) controls both bone formation and osteoclastogenesis via osteoblasts and/or osteocytes. Cx43 has also been…”
Get full text

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma by Watkins, Marcus P., Fanale, Michelle A., Bartlett, Nancy L.

“…Until recently, advances in classic Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and…”
Get full text

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma by Jaswal, Shama, Sanders, Vanessa, Pullarkat, Priyanka, Teja, Stephanie, Salter, Amber, Watkins, Marcus P, Atagu, Norman, Ludwig, Daniel R, Mhlanga, Joyce, Mellnick, Vincent M, Peterson, Linda R, Bartlett, Nancy L, Kahl, Brad S, Fehniger, Todd A, Ghobadi, Armin, Cashen, Amanda F, Mehta-Shah, Neha, Ippolito, Joseph E

“…In many cancers, including lymphoma, males have higher incidence and mortality than females. Emerging evidence demonstrates that one mechanism underlying this…”
Get full text

Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome by Fakhri, Bita, Cashen, Amanda F., Duncavage, Eric J., Watkins, Marcus P., Wartman, Lukas D., Bartlett, Nancy L.

Get full text

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis by Epperla, Narendranath, Zhao, Qiuhong, Moyo, Tamara, Watkins, Marcus P., Tavakkoli, Montreh, Bello, Celeste, Torka, Pallawi, Reddy, Nishitha, Thomas, Colin, Annunzio, Kaitlin, Christian, Beth, Barta, Stefan K., Shouse, Geoffrey, Olszewski, Adam J., Bartlett, Nancy L.

Get full text

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303 by Russler-Germain, David A., Krysiak, Kilannin, Ramirez, Cody, Mosior, Matthew, Watkins, Marcus P., Gomez, Felicia, Skidmore, Zachary L., Trani, Lee, Gao, Feng, Geyer, Susan, Cashen, Amanda F., Mehta-Shah, Neha, Kahl, Brad S., Bartlett, Nancy L., Alderuccio, Juan P., Lossos, Izidore S., Ondrejka, Sarah L., Hsi, Eric D., Martin, Peter, Leonard, John P., Griffith, Malachi, Griffith, Obi L., Fehniger, Todd A.

“…•MAP (CREBBP, STAT6, TP53, IGLL5, B2M, SOCS1, and MYD88) confer adverse risk when found at FL diagnosis.•Low-risk m7-FLIPI is predictive of prolonged…”
Get full text